Back to Search Start Over

Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020.

Authors :
Kilburn S
Innes G
Quinn M
Southwick K
Ostrowsky B
Greenko JA
Lutterloh E
Greeley R
Magleby R
Chaturvedi V
Chaturvedi S
Source :
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Mar 15; Vol. 66 (3), pp. e0224221. Date of Electronic Publication: 2022 Jan 10.
Publication Year :
2022

Abstract

About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to <1% for New York C. auris clinical isolates but not for New Jersey, highlighting the regional differences.

Details

Language :
English
ISSN :
1098-6596
Volume :
66
Issue :
3
Database :
MEDLINE
Journal :
Antimicrobial agents and chemotherapy
Publication Type :
Academic Journal
Accession number :
35007140
Full Text :
https://doi.org/10.1128/aac.02242-21